Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Q-VANT Biosciences
About us
Q-SAP Technology
Process and Quality Approach for adjuvants
R&D Approach for Adjuvants
Team
News
Adjuvants
Saponin Adjuvants
Human
QS-21 INFINITY
QS-21 GH
Veterinary
Security of supply
Importance of Supply Security and Affordability
The 100 Days Plan
Facilities
Biomass Supply
Vaccine formulation
Vaccine Formulation Guidance
Collaborations
Contact
Q-VANT Biosciences
About us
Q-SAP Technology
Process and Quality Approach for adjuvants
R&D Approach for Adjuvants
Team
News
Adjuvants
Saponin Adjuvants
Human
QS-21 INFINITY
QS-21 GH
Veterinary
Security of supply
Importance of Supply Security and Affordability
The 100 Days Plan
Facilities
Biomass Supply
Vaccine formulation
Vaccine Formulation Guidance
Collaborations
Contact
Monthly Archives
November 2024
Q-VANT manufacturing facility is operational
News
Q-VANT manufacturing facility is operational
Search
Recent Posts
Q-VANT manufacturing facility is operational
November 26, 2024
Q-Vant Collaborates with Tulane University to Develop a Promising New Oral Vaccine Adjuvant
February 9, 2024
Q-VANT and SPI Pharma Offering Broader Access to Sustainable and Scalable Pharma-grade Saponin Adjuvants
January 31, 2024
Archives
November 2024
February 2024
January 2024
March 2022
January 2022
October 2021
